menu
    • menu

    Company profile for Cyprium Therapeutics

    NEW Drugs in Dev: 3
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Cyprium Therapeutics, Inc. (Cyprium), a Fortress Biotech company, is focused on the development of novel therapies for the treatment of Menkes disease and related copper metabolism disorders. In March 2017, Cyprium entered into a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH)...
    Cyprium Therapeutics, Inc. (Cyprium), a Fortress Biotech company, is focused on the development of novel therapies for the treatment of Menkes disease and related copper metabolism disorders. In March 2017, Cyprium entered into a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH), to advance the clinical development of Phase 3 candidate CUTX-101 (Copper Histidinate injection) for the treatment of Menkes disease.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cyprium TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2 Gansevoort Street, 9th Floor New York, NY 10014
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cypriumtx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    IPhEB Russia

    Not Confirmed

    envelop Contact Supplier

    IPhEB Russia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cyprium Closes Sale for Priority Review Voucher for $205 Million
    Cyprium Closes Sale for Priority Review Voucher for $205 Million

    30 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/30/3265013/28889/en/Fortress-Biotech-s-Subsidiary-Cyprium-Therapeutics-Closes-Sale-of-Rare-Pediatric-Disease-Priority-Review-Voucher-for-205-Million.html

    GLOBENEWSWIRE
    30 Mar 2026
    Share Share
    Fortress Unit Cyprium Sells Rare Pediatric PRV For $205M
    Fortress Unit Cyprium Sells Rare Pediatric PRV For $205M

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3242632/28889/en/Fortress-Biotech-s-Subsidiary-Cyprium-Therapeutics-Enters-into-Agreement-to-Sell-Rare-Pediatric-Disease-Priority-Review-Voucher-for-205-Million.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Fortress Biotech and Cyprium Announce FDA Approve ZYCUBO
    Fortress Biotech and Cyprium Announce FDA Approve ZYCUBO

    12 Jan 2026

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211241

    FDA
    12 Jan 2026
    Share Share
    Fortress Biotech, Cyprium Therapeutics Announce FDA Acceptance
    Fortress Biotech, Cyprium Therapeutics Announce FDA Acceptance

    15 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/15/3205379/28889/en/Fortress-Biotech-and-Cyprium-Therapeutics-Announce-FDA-Acceptance-of-CUTX-101-NDA-Resubmission.html

    GLOBENEWSWIRE
    15 Dec 2025
    Share Share
    Fortress Bio, Cyprium Therapeutics Update NDA For CUTX-101
    Fortress Bio, Cyprium Therapeutics Update NDA For CUTX-101

    01 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/01/3159486/28889/en/Fortress-Biotech-and-Cyprium-Therapeutics-Announce-an-Update-on-the-NDA-for-CUTX-101.html

    GLOBENEWSWIRE
    01 Oct 2025
    Share Share
    FDA Accepts Fortress-Cyprium NDA For Menkes Disease Treatment
    FDA Accepts Fortress-Cyprium NDA For Menkes Disease Treatment

    06 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/06/3004566/28889/en/Fortress-Biotech-and-Cyprium-Therapeutics-Announce-U-S-FDA-Acceptance-and-Priority-Review-of-NDA-for-CUTX-101-for-Treatment-of-Menkes-Disease.html

    GLOBENEWSWIRE
    06 Jan 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search